Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development and is building a pipeline of monotherapies for novel targets and/or with novel payloads. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types which is expected to reach IND in 2024.
| Headquarters | London, UK |
| Website | www.pheontx.com |
| Pipeline Status | Preclinical |
| @PheonTx | |
| Pheon Therapeutics |